Study of Anonymized Clinical Data from Past Multiple Myeloma Trials Using Genomic, Clinical, and Imaging Information to Predict Disease Outcomes

What this Trial Is About

This research investigates multiple myeloma by analyzing previously collected genomic, clinical, and imaging data from past studies conducted at the Hematology Unit of IRCCS Azienda Ospedaliero-Universitaria di Bologna. The goal is to understand how these different types of information relate to disease outcomes and to create predictive models using artificial intelligence and machine learning that might forecast disease progression and treatment responses in the future. The study uses existing, pseudonymized data without requiring any new tests, procedures, or patient visits. The data includes genomic profiles from bone marrow and blood samples and imaging to describe disease distribution at baseline. Secondary measures will assess treatment response and early relapse within 18 months of therapy start. Participants are not actively involved since the study is retrospective and observational. Researchers will securely develop and store anonymized datasets for analysis. The main outcomes include detailed genomic descriptions and imaging data at baseline, with follow-up on therapy response and relapse rates. The study is planned to run until 2028.

Anonymization of Clinical Data From Pseudonymized Databases Collected as Part of Previus Clinical Trials on Multiple Myeloma